• Recently, Oscar Health was highlighted by Zacks as a top-ranked momentum and growth stock, citing its favorable Momentum and Growth Scores alongside an earnings-focused Zacks Rank #1.
• This recognition reflects how analysts currently view Oscar Health’s combination of earnings revisions, valuation metrics, and growth characteristics relative to its health insurance peers.
• We’ll now examine how Oscar Health’s new Zacks Rank #1 status and growth-screen inclusion may influence its existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Oscar Health Investment Narrative Recap

To own Oscar Health, you need to believe its tech-enabled insurance model can keep turning recent profitability and strong membership trends into enduring earnings, while controlling medical costs. Zacks’ new Rank #1 and growth-screen inclusion spotlight recent price momentum and earnings revisions, but they do not materially change the core near term story, which still hinges on sustaining margin improvement and managing the risk that medical costs or pricing approvals move against the company.

The most relevant recent development here is Oscar’s August 2026 guidance raise, which lifted 2026 revenue expectations to US$18.7–19.0 billion and Earnings from Operations to US$500–700 million. That update helps explain why earnings focused rankings have shifted, and it ties directly into the current catalyst of margin recovery. It also sharpens the risk that any setback in rate filings, utilization trends, or cost savings could challenge these upgraded targets and the optimism now reflected in the share price.

Yet against this improving story, investors should also be aware of how sensitive those upgraded earnings goals are to...

Oscar Health's narrative projects $23.8 billion revenue and $998.5 million earnings by 2029. This requires 21.4% yearly revenue growth and an earnings increase of about $1.0 billion from -$39.4 million today.

Uncover how Oscar Health's forecasts yield a $24.20 fair value, a 24% downside to its current price.

Exploring Other Perspectives

While Zacks highlights recent strength, the most pessimistic analysts still assume only about US$19.6 billion of revenue and US$923.9 million of earnings by 2029, showing how far opinions can differ and why it helps to compare these cautious forecasts with your own view before the latest momentum fully reshapes expectations.

Explore 9 other fair value estimates on Oscar Health - why the stock might be worth 24% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oscar Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

No Opportunity In Oscar Health?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.